Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology
In line with the general aims of the BAP guideline series, these guidelines are intended to translate recent research in the field of ADHD to promote improvements in diagnosis and treatment of this disorder. These guidelines are aimed at all those who deliver clinical care, commission treatment or are otherwise involved in the diagnosis and treatment of children, adolescents and adults with ADHD, including psychiatrists, general practitioners, psychologists, paediatricians, pharmacists, commissioners and user representatives. The guidelines encompass a comprehensive assessment of current literature on ADHD, ranging from aetiological research and neuroimaging to current trends in the development of treatment and services.
Read full Guideline